← Ablatotech Vitals
Psychiatry EvidenceDigest

Emerging Evidence on the Use of Anti-Glutamatergic Agents in Treatment-Resistant Bipolar Depression

Psychiatry · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
November 19, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Anti-glutamatergic agents, including esketamine and other NMDA receptor modulators, represent a promising but still investigational class of adjunctive treatments for patients with treatment-resistant bipolar depression (TRBD). Emerging evidence suggests potential rapid antidepressant effects distinct from traditional monoaminergic therapies, yet robust, large-scale clinical trials remain limited. Clinicians should consider these agents as putative options within a comprehensive treatment plan, recognizing the need for further validation and careful patient selection.

Clinical bottom line

Anti-glutamatergic agents, including esketamine and other NMDA receptor modulators, represent a promising but still investigational class of adjunctive treatments for patients with treatment-resistant bipolar depression (TRBD). Emerging evidence suggests potential rapid antidepressant effects distinct from traditional monoaminergic therapies, yet robust, large-scale clinical trials remain limited. Clinicians should consider these agents as putative options within a comprehensive treatment plan, recognizing the need for further validation and careful patient selection.

What the evidence shows

Treatment-resistant bipolar depression poses significant therapeutic challenges, with conventional antidepressants often yielding suboptimal outcomes or risking mood destabilization (Sienaert et al., 2012; Diaz et al., 2022). The glutamatergic system has gained attention due to its role in synaptic plasticity and mood regulation, prompting investigation into NMDA receptor antagonists and modulators as novel interventions.

Esketamine, the S-enantiomer of ketamine, is the first glutamatergic agent approved for treatment-resistant depression, with evidence supporting its rapid antidepressant effects (Musazzi et al., 2020). Although most esketamine data derive from unipolar depression populations, preliminary findings indicate potential benefits in bipolar depression, particularly as adjunctive therapy to mood stabilizers (Musazzi et al., 2020). The rapid onset of action contrasts with traditional antidepressants, which may take weeks to achieve clinical effect.

Other anti-glutamatergic agents, such as felbamate, have been explored in smaller clinical trials for TRBD, showing some efficacy signals but limited by sample size and methodological constraints (PsycEXTRA Dataset, 2008). Psychedelic agents with glutamatergic mechanisms are also under investigation for treatment-resistant depression broadly, though data specific to bipolar depression remain sparse (Gukasyan et al., 2022).

Systematic reviews highlight that while anti-glutamatergic agents may offer novel mechanisms and rapid symptom relief, evidence quality varies, and their role in bipolar depression is less well established compared to unipolar depression (Sienaert et al., 2012; Diaz et al., 2022). Adjunctive pramipexole and imipramine have been studied for TRBD but target dopaminergic and monoaminergic systems rather than glutamate (Raj et al., 2025; Trusso et al., 2016), underscoring the need for diverse mechanistic approaches.

Caveats and uncertainty

Current evidence for anti-glutamatergic agents in TRBD is limited by small sample sizes, heterogeneous study designs, and a paucity of randomized controlled trials specifically targeting bipolar populations. Esketamine’s approval and clinical use primarily focus on unipolar depression, and extrapolation to bipolar depression requires caution due to differing pathophysiology and risk of mood switching.

Safety profiles, long-term effects, and optimal dosing strategies for glutamatergic agents in bipolar depression remain incompletely characterized. Potential adverse effects, including dissociation and blood pressure elevation with esketamine, necessitate careful monitoring. The risk of inducing mania or hypomania is a particular concern in bipolar disorder, warranting vigilance.

Moreover, the heterogeneity of TRBD complicates treatment response prediction, and glutamatergic agents may benefit only a subset of patients. Biomarkers or clinical predictors to guide patient selection are not yet established.

How this may change practice

As evidence accumulates, anti-glutamatergic agents could become valuable adjunctive options for patients with TRBD who have failed multiple conventional therapies. Their rapid onset of antidepressant effect may address urgent symptom burden, including suicidality, when integrated with mood stabilizers to mitigate switching risk.

Clinicians should remain informed about ongoing clinical trials and emerging guidelines to judiciously incorporate these agents. Multidisciplinary collaboration and patient education regarding benefits, risks, and monitoring requirements are essential.

Future practice may include personalized approaches leveraging glutamatergic modulation, potentially in combination with pharmacogenomic or neurobiological markers, to optimize outcomes in this difficult-to-treat population.


References

  1. Sienaert P, et al. Evidence‐based treatment strategies for treatment‐resistant bipolar depression: a systematic review. Bipolar Disorders 2012;14:351-369. DOI:10.1111/bdi.12026
  2. Diaz AP, et al. Treatment-resistant bipolar depression. Managing Treatment-Resistant Depression 2022;:—. DOI:10.1016/b978-0-12-824067-0.00026-8
  3. Musazzi L, et al. Esketamine: the first glutamatergic drug for the management of treatment-resistant depression. Pharmadvances 2020;3:45-52. DOI:10.36118/pharmadvances.03.2020.02
  4. Anonymous, et al. Clinical trial of Felbamate for treatment-resistant bipolar depression. PsycEXTRA Dataset. 2008.
  5. Gukasyan N, et al. Psychedelic agents for treatment-resistant depression. Managing Treatment-Resistant Depression 2022;:—. DOI:10.1016/b978-0-12-824067-0.00014-1
  6. Raj K, et al. Treatment-Resistant Bipolar Depression: Is Adjunctive Pramipexole An Option? 2025. DOI:10.64239/pi-qt7801
  7. Allegra Trusso Maria, et al. Imipramine for treatment- resistant bipolar depression. 2016.

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team